Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with once-a-day dose

Pfiz­er won’t be mov­ing a twice-dai­ly for­mu­la­tion of its oral GLP-1, danuglipron, in­to Phase III af­ter the drug trig­gered high rates of gas­troin­testi­nal side ef­fects …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER